

Exhibit 13

G.P. Allaway et al., U.S. Serial No. 09/852,238, filed May 9, 2001

Pending claims:

49. An agent which comprises consecutive amino acids, which amino acids have a sequence identical to a sequence within a portion of an amino terminal domain of a CCR5 chemokine receptor, wherein the amino terminal domain of the CCR5 chemokine receptor is set forth in SEQ ID NO:5.
50. The agent of claim 49, wherein the consecutive amino acids have the sequence set forth in SEQ ID NO:5.
51. The agent of claim 49 or 50, wherein the consecutive amino acids are identical to the corresponding original consecutive amino acids present in the CCR5 chemokine receptor.
52. The agent of claim 49 or 50, wherein the consecutive amino acids are modified from the corresponding consecutive amino acids present in the CCR5 chemokine receptor.
53. The agent of claim 49 or 50, wherein the agent is a polypeptide.
54. A composition which comprises a carrier and an amount of the agent of claim 49 or 50 effective to inhibit HIV-1 infection of a CD4⁺ cell.
55. A method of inhibiting HIV-1 infection of a CD4⁺ cell which comprises contacting the CD4⁺ cell with the agent of claim 49 or 50 in an amount and under conditions such that fusion of HIV-1 or an HIV-1 infected cell to the CD4⁺ cell is inhibited, so as to thereby inhibit HIV-1 infection of the CD4⁺ cell.